Corvus Pharmaceuticals (CRVS) Assets Average (2022 - 2025)
Historic Assets Average for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $85.0 million.
- Corvus Pharmaceuticals' Assets Average rose 3773.75% to $85.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.0 million, marking a year-over-year increase of 3773.75%. This contributed to the annual value of $57.2 million for FY2024, which is 58.62% up from last year.
- Per Corvus Pharmaceuticals' latest filing, its Assets Average stood at $85.0 million for Q3 2025, which was up 3773.75% from $74.4 million recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Assets Average registered a high of $96.9 million during Q2 2022, and its lowest value of $42.8 million during Q1 2024.
- Over the past 4 years, Corvus Pharmaceuticals' median Assets Average value was $63.5 million (recorded in 2023), while the average stood at $66.2 million.
- Per our database at Business Quant, Corvus Pharmaceuticals' Assets Average crashed by 4003.13% in 2023 and then soared by 4987.1% in 2025.
- Over the past 4 years, Corvus Pharmaceuticals' Assets Average (Quarter) stood at $74.3 million in 2022, then crashed by 34.39% to $48.7 million in 2023, then surged by 31.0% to $63.9 million in 2024, then soared by 33.05% to $85.0 million in 2025.
- Its Assets Average stands at $85.0 million for Q3 2025, versus $74.4 million for Q2 2025 and $64.2 million for Q1 2025.